Helix Therapeutics (New Haven, CT) a preclinical-stage company developing triplex-forming oligonucleotides to target genome modification with a focused on hemoglobin, immune and lysosomal storage disorders, closed a $2.5M Series A financing. Participants include Canaan Partners and Connecticut Innovations.